Who Owns EirGenix Company?

EirGenix Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Holds the Reins at EirGenix?

Understanding a company's ownership is key to grasping its strategic direction and influence. EirGenix, a prominent CDMO for biologics, saw a significant boost with over $175 million in investments from figures like Foxconn founder Terry Gou in 2021, fueling its global expansion.

This substantial capital infusion highlights the importance of knowing who owns EirGenix and how their stakes shape its future. The company's journey began with a vision to provide high-quality, cost-effective CDMO services for biologics, making treatments more accessible.

EirGenix, Inc., established in 2012 and based in Taiwan, originated from the Development Center for Biotechnology (DCB). It operates two PIC/S GMP facilities, specializing in mammalian and microbial cell manufacturing. The company offers a full suite of services, from cell line development to cGMP manufacturing for biosimilars and novel biologics, including contributions to cancer treatment advancements. A detailed look at its market position can be found in the EirGenix Porter's Five Forces Analysis.

Currently, EirGenix remains a private entity, though an IPO was anticipated for December 27, 2024. With approximately 404 employees, the company has secured a total of $480 million in funding. Its growth reflects its comprehensive offerings in the biopharmaceutical sector, serving both biosimilar development and manufacturing for other industry players.

EirGenix Inc. was established on December 21, 2012. In mid-March 2013, a significant joint venture agreement was formed between EirGenix, Inc., Formosa Laboratories, Inc., and the Development Center for Biotechnology (DCB). This collaboration marked a pivotal moment in the company's early ownership structure.

Founding of EirGenix EirGenix Inc. officially commenced operations on December 21, 2012. This date signifies the formal inception of the company. Joint Venture Agreement A crucial joint venture agreement was signed in mid-March 2013. This involved EirGenix, Inc., Formosa Laboratories, Inc., and the Development Center for Biotechnology (DCB). Acquisition of Pilot Plant Facility Through this agreement, EirGenix acquired the operational rights to a cGMP biopharmaceutical pilot plant facility from DCB. This included the transfer of all associated technologies, R&D, and production personnel. Core Capabilities Transferred The transfer encompassed vital capabilities such as cell line establishment, large-scale production process development, and analytical method development. Certified Facilities EirGenix gained access to two cGMP facilities. These facilities held certifications from the US FDA, Taiwan FDA, and Japan PMDA. Founder's Expertise Dr. Lee-Cheng Liu is recognized as the founder, chairman, and president of EirGenix. He brought extensive experience to the company's establishment.

Dr. Lee-Cheng Liu, the founder, chairman, and president, brought a wealth of experience to EirGenix. His background included 30 years in product and process development, as well as manufacturing across the biotech, pharmaceutical, and specialty chemical sectors. While specific initial equity splits are not publicly detailed, the company's foundation was built upon the joint venture with Formosa Laboratories, Inc. and the acquisition of DCB's biopharmaceutical pilot plant facilities. This structure suggests an early ownership stake rooted in these entities and Dr. Liu's vision. Although specific early backers are not identified as traditional angel investors, the acquisition of established facilities and personnel from DCB implies significant initial investment and foundational support from a government-backed entity focused on biotechnology advancement. This strategic early setup aimed to accelerate biopharmaceutical development and manufacturing by leveraging existing infrastructure and expertise.

Early Ownership Structure

The initial ownership of EirGenix was shaped by its formation through a joint venture and the acquisition of key assets. This laid the groundwork for the company's operational capabilities and strategic direction.

• EirGenix Inc. was founded on December 21, 2012.
• A joint venture agreement was signed in mid-March 2013 with Formosa Laboratories, Inc. and the Development Center for Biotechnology (DCB).
• EirGenix acquired the rights to operate a cGMP biopharmaceutical pilot plant facility from DCB.
• This acquisition included the transfer of technologies, R&D, and production personnel.
• The company's founder, chairman, and president is Dr. Lee-Cheng Liu.
• Early investment was likely supported by the government-commissioned DCB, facilitating the acquisition of established infrastructure.

EirGenix SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership of EirGenix has seen significant shifts, particularly with its upcoming IPO and substantial funding rounds. Key investments have solidified its position and shaped its current stakeholder landscape.

EirGenix has attracted substantial investment, totaling $480 million across its funding history, including a significant Post IPO round of $90.6 million in September 2021. The company's evolution towards a public offering, scheduled for December 27, 2024, underscores its growth trajectory and the increasing confidence from major institutional and corporate investors. Understanding who owns EirGenix involves looking at a diverse group of entities that have strategically invested in its future.

Key Investors Driving EirGenix's Growth

EirGenix's ownership structure is influenced by significant capital injections from prominent entities. These investments are crucial for the company's expansion and development initiatives.

• Foxconn Technology Co., Ltd. is a major shareholder with a 9.10% stake.
• Yonglin Capital Holding Co., Ltd. holds 8.77% of the company's shares.
• Formosa Laboratories, Inc. is another significant stakeholder, owning 6.14%.
• The National Development Fund, Executive Yuan, has a 5.06% holding.
• Terry Gou's investment in 2021 marked a substantial private placement, positioning him as a key figure in the EirGenix company owner landscape.
• The company's funding rounds, including a Post IPO round of $90.6 million, highlight its appeal to a broad investor base, as detailed in the Competitors Landscape of EirGenix article.

EirGenix PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

EirGenix's board of directors is instrumental in its governance, reflecting the company's ownership dynamics. Dr. Lee-Cheng Liu, the founder, also serves as Chairman and President, leading a board composed of executive and independent directors.

The board's collective experience is substantial, with an average tenure of 8.8 years. While specific voting rights structures are not detailed, significant shareholders like Foxconn Technology Co., Ltd., holding 9.10%, and Yonglin Capital Holding Co., Ltd., with 8.77%, likely wield considerable influence through their board representation and equity. The board's responsibilities include overseeing corporate governance, approving financial reports, and authorizing capital-raising activities, such as the 2024 private placement of up to 30,000,000 common shares to enhance financial flexibility. Understanding these key individuals and their affiliations is vital for grasping EirGenix ownership and its overall company structure.

Key Aspects of EirGenix Board and Ownership

The board of directors at EirGenix is a mix of seasoned executives and independent voices, guiding the company's strategic direction.

• Dr. Lee-Cheng Liu is the founder and holds key leadership positions.
• Major shareholders like Foxconn Technology Co., Ltd. and Yonglin Capital Holding Co., Ltd. have significant stakes.
• The average tenure of board members is 8.8 years, indicating experience.
• The board approves crucial financial decisions and capital strategies, impacting EirGenix funding and investors.
• This structure provides insight into EirGenix company profile ownership details.

EirGenix Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the last three to five years, the ownership landscape of EirGenix has seen dynamic shifts, significantly influenced by strategic investments and upcoming public market transitions. These developments are reshaping its corporate structure and future trajectory.

Recent share buyback programs have also been a notable trend, impacting the number of outstanding shares and potentially altering proportional ownership for existing EirGenix stakeholders. For example, an equity buyback announced on December 16, 2024, concluded with the repurchase of 4,000,000 shares, representing 1.31% of the company's stock, for TWD 305.47 million. Additionally, in December 2024, the company authorized another buyback of 4,000,000 shares, also representing 1.31%, for TWD 6,357.55 million. These actions are part of a broader strategy to enhance shareholder value and refine the company's capital structure.

Strategic Investment Impact

The significant investment from Terry Gou in 2021 marked a pivotal moment, injecting substantial capital and bolstering EirGenix's capacity for global expansion. This influx of funds from prominent investors like Foxconn Technology Co., Ltd. and Yonglin Capital Holding Co., Ltd. underscores confidence in the company's growth potential.

Share Buyback Strategy

EirGenix's recent share buybacks are designed to reduce the number of outstanding shares. This can lead to an increase in earnings per share and potentially boost the stock price, benefiting remaining shareholders.

Transition to Public Listing

The planned Initial Public Offering (IPO) on December 27, 2024, signifies a major transition for EirGenix from a private to a public entity. This move will broaden its shareholder base and increase its visibility in the financial markets.

CDMO Industry Trends

Operating within the Contract Development and Manufacturing Organization (CDMO) sector, EirGenix is positioned to benefit from sustained market growth, with the global CDMO market valued at USD 185 billion in 2024. The increasing trend of outsourcing by pharmaceutical and biotech firms, coupled with industry consolidation, presents significant opportunities for strategic partnerships and acquisitions.

EirGenix Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔